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Abstract
Background: Several approaches have been used for measuring HIV incidence in large areas, yet each presents specific
challenges in incidence estimation.
Methodology/Principal Findings: We present a comparison of incidence estimates for Kenya and Uganda using multiple
methods: 1) Epidemic Projections Package (EPP) and Spectrum models fitted to HIV prevalence from antenatal clinics (ANC)
and national population-based surveys (NPS) in Kenya (2003, 2007) and Uganda (2004/2005); 2) a survey-derived model to
infer age-specific incidence between two sequential NPS; 3) an assay-derived measurement in NPS using the BED IgG
capture enzyme immunoassay, adjusted for misclassification using a locally derived false-recent rate (FRR) for the assay; (4)
community cohorts in Uganda; (5) prevalence trends in young ANC attendees. EPP/Spectrum-derived and survey-derived
modeled estimates were similar: 0.67 [uncertainty range: 0.60, 0.74] and 0.6 [confidence interval: (CI) 0.4, 0.9], respectively,
for Uganda (2005) and 0.72 [uncertainty range: 0.70, 0.74] and 0.7 [CI 0.3, 1.1], respectively, for Kenya (2007). Using a local
FRR, assay-derived incidence estimates were 0.3 [CI 0.0, 0.9] for Uganda (2004/2005) and 0.6 [CI 0, 1.3] for Kenya (2007).
Incidence trends were similar for all methods for both Uganda and Kenya.
Conclusions/Significance: Triangulation of methods is recommended to determine best-supported estimates of incidence
to guide programs. Assay-derived incidence estimates are sensitive to the level of the assay’s FRR, and uncertainty around
high FRRs can significantly impact the validity of the estimate. Systematic evaluations of new and existing incidence assays
are needed to the study the level, distribution, and determinants of the FRR to guide whether incidence assays can produce
reliable estimates of national HIV incidence.
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Introduction
Measuring HIV incidence or the rate of new HIV infections in a
population over time is of paramount importance for proper
planning and evaluation of HIV prevention programs. Several
methods have been proposed for measuring HIV incidence in
large areas, yet each presents specific challenges [1,2].
The original ‘‘gold standard’’ method for measuring population-
level HIV incidence is a prospective cohort study that measures
the occurrence of new infections in a well-defined HIV-negative
population followed over time and tested at regular intervals for
HIV infection. These studies, however, are rare, difficult and
expensive to implement, and prone to biases that could reduce
generalizability of results.
Most developing countries approximate adult HIV incidence
using mathematical models that relate observed HIV prevalence
to HIV incidence, which make assumptions on the average
survival of HIV-infected individuals and the effect of antiretroviral
(ARV) treatment on survival [3,4]. In countries with generalized
epidemics, the primary sources of HIV prevalence data for these
models are routine unlinked and anonymous HIV sero-surveys
among pregnant women attending antenatal clinics (ANC) and
nationally representative population-based surveys (NPS) with
HIV testing, including demographic health surveys (DHS) and
AIDS indicator surveys (AIS) [5]. NPS have also been used to
derive age-specific HIV incidence rates in the general population
using HIV prevalence data from two sequential surveys in the
country [6,7,8,9]. This method has been broadly validated
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17535
through comparison with cohort measures of incidence and has
been applied to several settings where two such surveys exist.
HIV incidence assays are a laboratory-based approach for
detecting recently acquired HIV infection in cross-sectional
samples of HIV-positive specimens and designed to estimate
population-level HIV incidence [10,11,12]. These assays are based
on the principle that antibody response to HIV infection matures
over time and that immunological biomarkers of HIV disease
progression can be used to distinguish recent from non-recent HIV
infection. The ideal assay has the property that all HIV-infected
persons will eventually produce a non-recent test result. The mean
time it takes to cross over the defined threshold value defines the
assay’s duration of recency (v) [13]. Incidence rates are estimated
by combining the number testing as recent on the assay, the mean
duration of recency for the assay, and the number at risk for recent
HIV infection in an incidence formula [10,14]. To correct for
individuals in a population who fail to progress out of the stage
marked as ‘recent’ by the assay [13,15], the application of
statistical adjustments in the incidence formula is required
[14,16,17,18]. A critical component to these adjustments is the
assay’s false-recent rate (FRR), defined as the probability that a
chronically infected individual (that is, an HIV-infected individual
infected .12 months) will misclassify as recent on the incidence
assay. Some HIV-infected individuals that are undergoing
treatment with ARVs will also misclassify as recent on the assay
as a result of enhanced viral suppression and corresponding
decrease in antibody response [19,20,21]. Because of the
significant impact that ARV use can have on incidence assay test
results, all FRR and incidence surveys should have the ability to
detect individuals that are currently taking ARVs to appropriately
account for these individuals in the analysis. Additionally, auxiliary
information on markers of advanced infection that could
potentially impact the FRR to a large degree, including duration
of HIV infection, CD4 cell counts, and age should also be
collected to determine whether FRR varies significantly by these
factors [6].
The most commonly used FRR value to date was derived for
the BED IgG capture enzyme immunoassay (hereafter referred to
as the BED assay) among a cohort of post-partum women followed
from 1997-2001 in Zimbabwe. This study calculated a FRR of
5.2% [CI 4.4, 6.1] [16] among 2,749 women with long-term
infections that were presumably not taking ARV treatment. The
Zimbabwe FRR had been recommended as the default FRR value
to use in settings that do not have a locally-relevant estimate of the
FRR for the BED assay [18]; however, the universal applicability
of the Zimbabwe FRR is unclear given that the FRR was
estimated to be 1.7% in neighboring South-Africa [23].
In Uganda, impressive declines in HIV prevalence were
documented from peak prevalence in the early 1990s at .10%
to an estimated 6% in the early 2000s [24,25,26,27]. More
recently, there is evidence that HIV prevalence and incidence are
no longer decreasing [28]. In Kenya, HIV prevalence has not
changed significantly in recent years, with national surveys
showing HIV prevalence at 6.7% in 2003 and 7.1% in 2007
[29,30]. National adult prevalence was estimated at 7.5%
[uncertainty range: 7.0, 7.9] in 2008, using UNAIDS Estimates
and Projections Package (EPP) [31].
As countries gather multiple sources of incidence data, there is
an opportunity to synthesize these data to determine the best
supported level of incidence and incidence trends in populations.
We compared several approaches for estimating incidence levels
and trends among adults in the general populations of Uganda and
Kenya. We used the availability of four different types of incidence
methods to draw comparisons between the approaches.
Methods
Available HIV Surveillance Data
HIV prevalence data for urban and rural ANC clinics were
available for Uganda from 1990–2007 and for Kenya from 1990–
2005. NPS with HIV testing were conducted in Uganda in 2004/
2005 (UAIS) and in Kenya in 2003 (KDHS) and 2007 (KAIS). To
allow comparisons across results obtained with different methods,
we restricted the analysis to adults aged 15–49 years.
Mathematically Modeled Incidence in the Year of the
Survey: Estimation and Projection Package (EPP)/
Spectrum Models of Incidence in the General Population
The EPP and Spectrum software packages are used widely by
countries in sub-Saharan Africa to produce national estimates
and projections for HIV/AIDS, including indirect estimates of
national adult HIV incidence. For this analysis, EPP was used to
fit a simple 4-parameter epidemiological model to observed HIV
surveillance data from ANC, calibrated to HIV prevalence data
from NPS, using a maximum likelihood method separately for
urban and rural areas. Bayesian melding was used to generate
multiple curves reflecting the uncertainty in the prevalence data
[3]. Adult HIV incidence for men and women combined was
calculated from HIV prevalence over time using assumptions
about the average survival of HIV-infected people and the effect
of ARV treatment on survival. Urban and rural curves were
combined into a set of national adult incidence curves over time.
Using the Spectrum software these time trends of incidence and
prevalence were then combined with country-specific demo-
graphic information [4]. Monte-Carlo simulations varying the
above inputs were used to generate uncertainty ranges about the
incidence estimates.
Mathematically Modeled Incidence in the Year of the
Survey: Survey-derived Models of Incidence from NPS
A mathematical method for estimating incidence from two
sequential NPS with HIV testing was applied [7,8,9]. In Kenya
where two NPS (2003 KDHS and 2007 KAIS) were available
[29,30], we assumed that individuals of age a in the 2003 KDHS
were represented by individuals aged azt in the 2007 KAIS,
where t is the interval between surveys. The change in HIV
prevalence among individuals of age a in the 2003 KDHS and in
the 2007 KAIS was attributed to incident infections and AIDS
deaths. The rate of AIDS death was based on the observed
distribution of survival after HIV infection [32], and estimated
HIV incidence for each age-group. In Uganda where only one
NPS with HIV testing was available (2004/2005 UAIS), the same
procedure was applied using a theoretical earlier survey to derive
an earlier estimate of HIV incidence and assuming that HIV
prevalence was constant in the five years preceding the survey.
This assumption is consistent with data reported from national
ANC surveillance [33] and a community-based cohort study in
Uganda [28] which suggest stable HIV prevalence during that
period. To the extent that real HIV prevalence rates were
fluctuating, this estimate could be inaccurate and is considered in
the interpretation of the results.
The effect of ARV use on HIV survival was accounted for by
removing the fraction of HIV-infected individuals that were alive
due to treatment in each survey [7]. To do this, data on ARV
treatment scale-up in each country [34,35,36,37] were used as
were the assumptions that (1) ARV treatment was initiated one
year before expected AIDS death [38] and (2) the age/sex-
distribution of those on ARV was approximated by the
HIV Incidence in Kenya and Uganda
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distribution of AIDS deaths projected using Spectrum and
published HIV prevalence trend data [4]. The survey-derived
method does not account for the uncertainty introduced in the
context of increased availability of ARV treatment. However,
these assumptions have been validated previously [8,39,40].,
Given that large scale up of ARV treatment programs have only
recently occurred in Kenya and Uganda, we do not anticipate
that ARV use significantly impacted the relevance of the
mortality assumptions used in this analysis. A 95% bootstrap
interval was calculated to quantify uncertainty in the incidence
estimates due to random sampling errors in the HIV prevalence
estimate.
Assay-derived Incidence in NPS
The BED assay was applied to frozen HIV-positive dried blood
spot samples from the 2003 KDHS [29] and serum samples from
the 2007 KAIS [30] and the 2004/2005 UAIS [41]. Assay-derived
HIV incidence and 95% confidence intervals (CI) were calculated
using the recommended formula for assay-derived incidence
estimation [15] and calibrated using the Zimbabwe FRR of
5.2% recommended for countries without local-derived FRR [16].
Estimates were also calibrated using a locally-derived FRR
estimated from a cross-sectional sample of specimens from
individuals residing in Rakai and Tororo districts in Uganda with
chronic HIV infection and who were not known to be taking
ARVs to treat their infection. Normally distributed errors around
the FRR were assumed in the calculation of assay-derived
incidence estimates.
A mean duration of recency of 155 days for the BED assay was
applied to estimate annualized assay-derived incidence rates [42].
All assay-derived estimates in the NPS were weighted using
individual sampling weights to generate national estimates of HIV
incidence. Incidence estimates were adjusted to account for HIV
positive specimens with missing BED assay test results, and 95%
CIs around the estimates were calculated.
Community Cohorts
A literature search of published papers and conference abstracts
reporting HIV incidence rates from community-based cohort
studies in Uganda and Kenya from 1990 to present was
conducted. Three community-based cohort studies in rural
Uganda, in Kayunga, Masaka and Rakai districts [28,43,44] were
identified. Annual incidence rates (and their 95% CIs when
reported) were abstracted by calendar year. For the Masaka cohort
the average of published annual incidence rates for males and
females aged .15 years was calculated and reported by calendar
year.
Trends in HIV Prevalence among Young Women Aged
15–24 Years Attending ANC Clinics, 2000–2007
HIV prevalence data collected from young pregnant women
(aged 15–24 years) attending ANCs between 2000–2007 in
Uganda and between 2000–2005 in Kenya were used as a proxy
for HIV incidence trends in the general population [1]. Sites that
were consistently included in national surveillance over time were
included in the analysis. Regression analysis was used to assess the
average change in prevalence per year in urban and rural areas.
Linear regression provided the best fit to data in Uganda while
exponential curves were fitted to the Kenyan data.
Comparing Incidence Levels and Trends
Testing for differences in incidence level in a specific year was
completed using the z-test statistic. Trends in EPP/Spectrum
estimates from 2000–2005 in Kenya and 2000–2007 in Uganda
were assessed for significance using a t-test statistic. Prevalence
trends among young pregnant women attending ANC over time
were considered statistically significant if the regression coefficients
were significantly different from zero. HIV incidence estimates
during the years of the NPS were compared to HIV prevalence
estimates from the NPS to assess plausibility of the incidence level,
using assumptions that national HIV incidence levels should not
be substantially higher or lower than 10% that of national HIV
prevalence levels in stable and mature epidemics.
Results
Calculation of a Local FRR in Samples of Known Long-
term Infection
The Uganda FRR was estimated by pooling published data
from FRR surveys in the Rakai Health Science Project (n = 473)
from 2004–2007 and the Home Based AIDS Care program in
Tororo District (n = 226) from 2003–2005 [20,21]. Overall,
among 699 specimens from HIV-infected persons who were
known to be infected for .12 months and not known to be on
ARV, 104 specimens classified as recent on the assay, resulting in a
local FRR of 14.9% [CI 12.2, 17.5] for the BED assay.
Comparison of Incidence Level
In the 2004/2005 UAIS, the total number of individuals
participating in the NPS was 18,525. Of these, 1,092 were HIV-
antibody positive, 1,023 had BED assay test results, and 172 tested
recent on the assay. Availability of ARV treatment programs was
presumed to be negligible in 2004 and not believed to have
affected the BED assay test results. Weighted assay-derived
incidence was 1.9% [CI 1.4, 2.3] using the Zimbabwe FRR and
0.3% [CI 0, 0.9] using the Uganda FRR (Table 1). The EPP/
Spectrum incidence was 0.68% [uncertainty range: 0.61, 0.75] in
2004 and 0.67% [uncertainty range: 0.60, 0.74] in 2005. Survey-
derived incidence was 0.6% [CI 0.4, 0.9] in 2005. Incidence in the
Masaka cohort was 0.49% in 2004 and 0.25% in 2005 and
prevalence was 7.7% [28]. In Rakai district, incidence was 1.24%
for a prevalence of 11.4% in 2002, and in Kayunga district in
2007, incidence was 0.8% [CI 0.3, 1.2] for a prevalence of 9.9%
[CI 8.6, 11.2] [43,44]. National HIV prevalence from the 2004/
2005 UAIS was 6.4% [CI 6.0, 6.7] [45].
In the 2003 KDHS, the total number of survey participants was
5,994. Of these, 399 were HIV-antibody positive, 362 had BED
assay test results, and 70 tested recent on the assay. Similar to
Uganda, the availability of ARV treatment programs in Kenya in
2003 was insignificant to have made an impact on test results.
Weighted assay-derived incidence was 2.5% [CI 1.7, 3.3] using the
Zimbabwe FRR and 0.8% [CI 0, 1.8] using the Uganda FRR.
The EPP/Spectrum incidence was 1.04% [uncertainty range:
1.03, 1.09]. National HIV prevalence from the 2003 KDHS was
6.7% [CI 5.8, 7.6] [29].
In the 2007 KAIS, the number of survey participants was
15,844. Of these, 1,098 were HIV- antibody positive, 876 had
BED assay test results, and 151 were BED recent. A total of 92
participants that reported current ARV use and were later
excluded from the incidence analysis. In 2007, EPP/Spectrum
incidence was 0.72% [uncertainty range: 0.70, 0.74], survey-
derived incidence was 0.7% [CI 0.3, 1.1], and weighted assay-
derived incidence was 2.1% [CI 1.6, 2.6] and 0.6% [CI 0, 1.3]
using the Zimbabwe and Uganda FRR, respectively. The KAIS
reported a national HIV prevalence of 7.4% [CI 6.7, 8.1] in 2007
[30].
HIV Incidence in Kenya and Uganda
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Comparison of Trends
In Kenya, the EPP/Spectrum incidence was stable at
approximately 1% from 2000–2003 and declined significantly
from 2003–2007, where incidence was estimated at 0.7%
(Figure 1). Using the Zimbabwe FRR, assay-derived incidence
was 2.5% in the 2003 KDHS and 2.1% in the 2007 KAIS. Using
the Uganda FRR, assay-derived incidence was 0.8% in the 2003
KDHS and 0.6% in the 2007 KAIS. HIV prevalence among
young ANC attendees aged 15–24 years in Kenya indicated a
significant decline between 2000 and 2005 overall (p,0.001) and
for both urban (p,0.001) and rural (p,0.001) areas (Figure 2).
In Uganda, EPP/Spectrum incidence remained stable at
approximately 0.7% from 2000–2007 (Figure 3). In the Rakai
cohort, HIV incidence was 1.2% in 2000 and 1.2% in 2002. In the
Masaka cohort, HIV incidence was 0.5% in 2000, 0.7% in 2002,
0.5% in 2004, and 0.4% in 2006. HIV prevalence trends among
young ANC attendees aged 15–24 years in Uganda showed a
slight non-significant increase from 2000–2007 in both urban and
rural areas (Figure 4).
Discussion
Comparison of assay-derived incidence to modeled estimates of
incidence provided evidence that when calibrating assay-derived
incidence based on the Zimbabwe FRR of approximately 5%,
assay-derived incidence estimates were inconsistent with those
obtained by other methods in both Kenya and Uganda. The
application of a local FRR of approximately 15% resulted in
assay-derived incidence estimates that were reasonably consistent
to estimates by other methods in Kenya. In Uganda, assay-derived
estimates were two times lower than modeled estimates and similar
to cohort-derived incidence reported in the same year. The
differences observed were not statistically significant. In the
analysis of incidence trends, results obtained by the different
methods appeared to correspond fairly well with each other. In
Uganda, incidence was stable from 2000–2007. In Kenya,
incidence appeared to have declined since 2000 by all approaches.
Comparisons of prevalence and incidence levels in the three
NPS confirm that the incidence estimates from all methods (i.e.,
EPP/Spectrum, the survey-derived method, and assay-derived
method using the Uganda FRR) fell within plausible levels for
Kenya in 2003 and 2007 (e.g., incidence estimates were 8–15%
that of observed HIV prevalence in the same population). In
contrast, in Uganda, the two mathematical models of incidence
produced plausible levels of incidence (e.g., incidence estimates
were approximately10% of prevalence), but assay-derived and
cohort-derived incidence estimates were both lower, falling at
approximately 4–5% of the prevalence level. The application of
the Zimbabwe FRR produced implausible levels of incidence, at
levels approximately 30–40% of prevalence, in all three surveys.
These findings confirm that BED assay-based incidence
estimates must incorporate a FRR in the incidence calculation
to account for false-recent classifications [14,22,46,47]. There is
less certainty, however, in choosing which FRR value to apply
given the sensitivity of the incidence estimate to the value of the
FRR. The Zimbabwe FRR had previously been shown to work
well in the setting in which it was estimated in Zimbabwe [16], but
did not result in reliable measures of incidence in Kenya and
Uganda. Moreover, though the application of a local FRR from
Uganda improved the plausibility of the assay-derived incidence
estimate for both Kenya and Uganda, the wide confidence
intervals around the estimates made it difficult to interpret these
findings.
Given the widely differing values for BED FRRs obtained in
studies with relatively large sample sizes in South Africa (1.7%),
Zimbabwe, (5%), China (6%), and in Uganda (15%) [16,21,23,48],
it is clear that more BED FRR studies that are conducted
systematically and powered sufficiently are needed to derive this
factor in other settings before a determination can be made whether
FRR values for the BED assay can be appropriately applied to
Table 1. HIV Incidence and Prevalence Rates in the Year of the National Survey, by Estimation Method, Kenya and Uganda.
Uganda Kenya
2004 2005 2003 2007 f
Rate 95% range Rate 95% range Rate 95% range Rate 95% range
HIV Incidence*
EPP/Spectrum 0.68 0.61, 0.75 0.67 0.60, 0.74 1.04 1.03, 1.09 0.72 0.70, 0.74
Survey-derived{,{ 0.6 0.4, 0.9 0.7 0.3, 1.1
Assay-derived: Zimbabwea 1.9 1.4, 2.3 2.5 1.7, 3.3 2.1 1.6, 2.6
Assay-derived: Ugandaa,b,c 0.3 0.0, 0.9 0.8 0.0, 1.8 0.6 0.0, 1.3
Cohort incidenced
Masakae 0.49 0.25
HIV Prevalence 6.4 6.0, 6.7 6.7 5.8, 7.6 7.4 6.7, 8.1
*Among adults aged 15–49 years.
{Uganda 2000–2005.
{Kenya 2003–2007.
a. All assay-derived estimates were weighted to account for unequal probability of selection and adjusted for non-response, where necessary. For the 2007 Kenya
estimate, any participant that reported current ARV use was excluded from the incidence analysis.
b. The Uganda FRR was generated from: (1) pooled data from 699 ARV naive long-term specimens from Rakai (76/473) and rural Tororo districts (28/226) in Uganda that
classified as false-recent on the BED assay.
c. Statistically significant difference observed in assay-derived estimate and the EPP/Spectrum estimate in Uganda 2005.
d. No data published on community cohort incidence in Kenya.
e. 95% confidence intervals not reported.
f. All participants that that reported current ARV use were excluded from the 2007 Kenya HIV prevalence estimate.
doi:10.1371/journal.pone.0017535.t001
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estimate population-level incidence; whether a local FRR obtained
in one country is applicable for all regions within a country and to
other countries of close geographic proximity and similar HIV
subtypes; and whether the value varies significantly over the course
of the epidemic. Another parameter required for estimating assay-
derived incidence is the assay’s mean duration of recency. Evidence
suggests that there may be significant variation in the mean duration
of recency across various populations and HIV clades [16,49]. If
used consistently, the value of this parameter should not affect the
analysis of incidence trends. However, because the incidence level
Figure 1. Trends in HIV incidence by estimation method, adults aged 15–49 years, Kenya, 2000–2007.
doi:10.1371/journal.pone.0017535.g001
Figure 2. Trends in HIV prevalence among young women aged 15–24 years attending antenatal clinics in Kenya, 2000–2005.
doi:10.1371/journal.pone.0017535.g002
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will be impacted, local estimates of the mean duration of recency
may be required to obtain accurate estimates of incidence in a given
population. These issues highlight the need for systematic
evaluations of the performance characteristics for new and existing
incidence assays using standardized methods and well characterized
specimen sets. Such an endeavor would require a central specimen
repository to be established as a standard resource for these
evaluations and to maximize comparability across assays. Speci-
mens in this repository should cover large volumes of specimen
panels from HIV seroconverter cohorts and individuals with
chronic HIV infection across a wide of geographic settings, viral
clades, and epidemic stages [50].
There is clear evidence that specimens from HIV-infected
persons that are currently on ARV treatment have a high
probability of falsely classifying as recent on an incidence assay
and that this error varies significantly by time on ARV [20,51].
Until an incidence assay that is not impacted by ARV use is
available, current incidence assays should only be applied to
settings where ARV use can be measured, either on the basis of
survey participants’ self-report [30] or by using laboratory
methods to test for the presence of ARV markers in the blood.
Though the latter approach may be more robust than self-report
data, limitations still exist that can affect the accuracy of the test
such as immediate metabolism of ARVs in the liver. Specimens
that test recent on the assay but have confirmed evidence of ARV
use can either be excluded from the incidence analysis or
reclassified as non-recent on the assay to produce a valid estimate
of incidence. While exclusion is an acceptable approach for
analysis of assay-derived incidence data, it may result in
uncertainty bounds that are wider than necessary [22]. Finally,
care must be applied to ensure that the population targeted in the
FRR survey and that for the incidence survey are similar with
respect to demographics, HIV subtypes, epidemic history, and
ARV treatment roll-out; else, the assay-derived incidence
estimates will not be reliable. For example, if the FRR is estimated
from specimens with persons with longstanding HIV infection and
not on ARV, the incidence survey must also exclude such persons
from incidence estimation.
Figure 3. Trends in HIV incidence by estimation method, adults aged 15–49 years, Uganda, 2000–2007.
doi:10.1371/journal.pone.0017535.g003
Figure 4. Trends in HIV prevalence among young women aged 15–24 years attending antenatal clinics in Uganda, 2000–2007.
doi:10.1371/journal.pone.0017535.g004
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The two indirect measurements of incidence in this analysis fell
within a plausible range of HIV incidence in both countries.
Though the survey-derived model was able to infer incidence
using one NPS, this required an assumption of stable HIV
prevalence in the preceding 5 years. This assumption was relevant
for Uganda given documented evidence of stable HIV prevalence
in the general population, but may not be for other countries
considering this approach. If stable prevalence cannot be
guaranteed for a given setting, it is recommended that this
approach not be used until at least two NPS are available [7,9].
The EPP/Spectrum estimate utilizes routinely collected data
from ANC surveillance together with data from NPS to estimate
national level adult incidence; therefore this approach remains an
attractive method for estimating national incidence in generalized
epidemics where these data are likely to exist. The advantage of
mathematical models for incidence estimation is that they are easy
to use, particularly if the model’s input data can be easily accessed
and are of good quality. A limitation, however, is that high quality
data cannot be guaranteed for some countries due to incomplete
reporting and lack of quality control measures in place.
Additionally, a degree of uncertainty is associated with the
modeled estimates given that they depend both on the structure
of the model and on assumptions regarding key parameters which
cannot always be determined directly from data for a specific
country of interest. Though the assumptions in the EPP/Spectrum
model are based on best available data, any errors in the model
assumptions (example.g., with respect to survival of HIV-infected
persons and ARV use) could impact the quality of the estimates.
Further, at the time of writing these models have only been used to
estimate incidence by age, sex and location but not by other
characteristics (i.e., behaviors, marital status or income level)
which may be useful for intervention planning. Finally, because
both countries had collected nearly 20 years of ANC surveillance
data and had completed one to two national HIV prevalence
surveys, the corresponding prevalence and incidence estimates in
the EPP/Spectrum models were constrained to narrow bounds
which may not reflect the full uncertainty.
Prospective community cohort studies are commonly regarded
as the ‘‘gold-standard’’ measure for community-level incidence
because incidence can be directly observed in the sample. In this
analysis, the main limitation of cohort studies is that they were
conducted in limited geographical areas. The Rakai community
cohort, for which only early years of incidence were available,
reported substantially higher rates of incidence compared to other
approaches for estimating population-level incidence. However
the reported HIV prevalence level in Rakai in 2002 was nearly two
times Uganda’s national HIV prevalence in the 2004/2005 AIS.
In contrast, the Masaka and Kayunga cohort studies, conducted in
areas with lower prevalence than Rakai, reported incidence
estimates that were lower than those observed in Rakai but
consistent with the measures of incidence obtained with indirect
methods for the same time period.
This analysis was subject to methodological issues that may
have biased the interpretation of the results. First, the level of the
Uganda FRR observed in this analysis was remarkably high.
High levels of the FRR will result in large uncertainty in the
assay-derived incidence estimate, rendering it difficult to interpret
and use these data. Incidence assays that produce consistently low
levels of the FRR in a variety of populations are optimal to ensure
assays can reproduce valid estimates of incidence for all settings.
To guide the development of improved incidence assays, a new
target product profile has set the minimum acceptable value of a
FRR at ,2%, with a coefficient of variation ,30%, for multiple
HIV subtypes and geographic settings [22,50]. Second, the
Ugandan FRR was derived from adults residing in two
geographic regions in Uganda (i.e., rural districts in Eastern
and Southwestern Uganda) which may not have been represen-
tative of the broader national populations in this analysis and may
have impacted the accuracy of the assay-derived estimates. To
minimize this bias, the FRR should be estimated in a population
that is representative of the one in which the incidence assay will
be applied for incidence estimation. For example, if national
incidence is desired, the FRR should be estimated in nationally
representative samples. Additionally, the FRR may vary by the
duration of the epidemic [6,13], precluding the application of a
standard local FRR over time. Though the Uganda FRR did not
vary significantly by proxy variables for stage of HIV epidemic
[e.g., duration of infection up to 12 years or by age (unpublished
data)], given the uncertainty around the FRR, investigators
should exhibit caution when applying this value and consider
repeatedly measuring the FRR in a representative population
over time. If this value is recent or there is evidence that the FRR
does not vary over time, it can be incorporated into the incidence
formula and expected to result in a significantly improved
estimate. Moreover, if improved incidence assays can demon-
strate consistently low FRR values in all settings, the need for
continued measurement of the FRR prior to conducting
incidence surveys will be greatly reduced [50]. Finally, this
analysis did not report on age, sex, or geographic estimates of
incidence, all of which are expected to vary substantially from
national HIV incidence estimates in Kenya and Uganda.
The use of HIV prevalence among young pregnant women
aged 15-24 years over time has been used as a surrogate measure
for trends in incidence [1,52]. As the onset of sexual activity in this
age group is recent, prevalence is expected to reflect recent
infections. However, a limitation in this approach is that it does
not inform trends among men nor women aged .25 years.
Depending on the surveillance system coverage, the data may not
be representative of all regions of the country [53]. Nonetheless,
we did find that observed trends in prevalence among ANC
attendees aged 15–24 years corresponded well with observed
trends in incidence in the overall population obtained through
mathematical modeling and published cohort data.
In conclusion, in combination, multiple methods for estimating
incidence in Kenya and Uganda appeared to converge in similar
trend and levels, yet on an individual basis, each of the approaches
have their limitations. It is evident that much work is still needed in
the area of assay-derived incidence estimation. Systematic
evaluations of incidence assays will help to determine whether
this method can accurately and precisely measure incidence.
Further, recent infection testing algorithms using a multiple
incidence assays in combination with additional clinical (e.g., CD4
cell count, RNA testing), laboratory (e.g., ART testing), and
historical information should be explored for improving the
accuracy of assay-derived incidence estimates. Pending the
development of improved incidence assays, we recommend
triangulation of multiple methods for incidence estimation and
interpretation of results in conjunction with other epidemiologic
data (e.g., HIV prevalence in the same population) to assess
plausibility of incidence trends and level in a country and use these
data to improve programmatic and policy decisions in the national
HIV response.
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